OUTLOOK THERAPEUTICS INC (OTLK)
US69012T3059 - Common Stock
We assign a fundamental rating of 1 out of 10 to OTLK. OTLK was compared to 561 industry peers in the Biotechnology industry. OTLK has a bad profitability rating. Also its financial health evaluation is rather negative. OTLK does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year OTLK has reported negative net income.
In the past year OTLK has reported a negative cash flow from operations.
In the past 5 years OTLK always reported negative net income.
In the past 5 years OTLK always reported negative operating cash flow.
1.2 Ratios
OTLK has a Return On Assets of -199.71%. This is amonst the worse of the industry: OTLK underperforms 90.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -199.71% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-215.73%
ROA(5y)-221.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
OTLK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OTLK has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, OTLK has more shares outstanding
OTLK has a worse debt/assets ratio than last year.
2.2 Solvency
OTLK has an Altman-Z score of -20.30. This is a bad value and indicates that OTLK is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -20.30, OTLK is doing worse than 87.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.3 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
OTLK has a Current Ratio of 1.07. This is a normal value and indicates that OTLK is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.07, OTLK is doing worse than 87.57% of the companies in the same industry.
OTLK has a Quick Ratio of 1.07. This is a normal value and indicates that OTLK is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.07, OTLK is not doing good in the industry: 85.41% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
OTLK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.04%, which is quite good.
EPS 1Y (TTM)18.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, OTLK will show a very strong growth in Earnings Per Share. The EPS will grow by 21.68% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.67%
EPS Next 2Y21.58%
EPS Next 3Y24.14%
EPS Next 5Y21.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
OTLK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OTLK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
OTLK's earnings are expected to grow with 24.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.58%
EPS Next 3Y24.14%
5. Dividend
5.1 Amount
No dividends for OTLK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OUTLOOK THERAPEUTICS INC
NASDAQ:OTLK (1/10/2025, 9:31:09 AM)
2.18
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners35.96%
Inst Owner Change-0.01%
Ins Owners0.32%
Ins Owner Change0.01%
Market Cap51.58M
Analysts85
Price Target33.32 (1428.44%)
Short Float %23.03%
Short Ratio1.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.16%
Min EPS beat(2)-78.78%
Max EPS beat(2)18.46%
EPS beat(4)3
Avg EPS beat(4)-5.55%
Min EPS beat(4)-78.78%
Max EPS beat(4)21.57%
EPS beat(8)5
Avg EPS beat(8)-7.97%
EPS beat(12)5
Avg EPS beat(12)-15.45%
EPS beat(16)6
Avg EPS beat(16)-18.48%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.3%
PT rev (3m)-12.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)14.05%
EPS NY rev (3m)14.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.18
EYN/A
EPS(NY)-2.51
Fwd EYN/A
FCF(TTM)-2.73
FCFYN/A
OCF(TTM)-2.73
OCFYN/A
SpS0
BVpS-3.54
TBVpS-3.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -199.71% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-215.73%
ROA(5y)-221.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | -20.3 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.13%
EPS Next Y6.67%
EPS Next 2Y21.58%
EPS Next 3Y24.14%
EPS Next 5Y21.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.49%
OCF growth 3YN/A
OCF growth 5YN/A